Array Form 4 BIOPHARMA / Ron Squarer ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Squarer Ron

(Last)

(First)

(Middle)

C/O ARRAY BIOPHARMA INC.

3200 WALNUT STREET

(Street)

BOULDER

80301

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ARRAY BIOPHARMA INC [ ARRY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2017

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/16/2017		M		23,437⁽¹⁾	A	$0.00	139,120⁽²⁾	D
Common Stock	12/16/2017		F		10,917⁽³⁾	D	$10.92	128,203	D
Common Stock	12/18/2017		M		226,874	A	$7.3	355,077⁽⁴⁾	D
Common Stock	12/18/2017		M		16,835	A	$5.94	371,912⁽⁴⁾	D
Common Stock	12/18/2017		M		110,800	A	$3.61	482,712⁽⁴⁾	D
Common Stock	12/18/2017		S⁽⁵⁾		273,438	D	$10.73⁽⁶⁾	209,274	D
Common Stock	12/19/2017		M		133,380	A	$3.61	342,654⁽⁴⁾	D
Common Stock	12/19/2017		M		79,688	A	$4.63	422,342⁽⁴⁾	D
Common Stock	12/19/2017		M		333,165	A	$5.94	755,507⁽⁴⁾	D
Common Stock	12/19/2017		S⁽⁵⁾		546,233	D	$10.93⁽⁶⁾	209,274	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0.00	12/16/2017		M			23,437	⁽⁷⁾	12/16/2020	Common Stock	23,437	$0.00	70,313⁽⁸⁾	D
Restricted Stock Units	$0.00	12/16/2017		A		100,000		⁽⁹⁾	12/17/2021	Common Stock	100,000	$0.00	100,000	D
Stock Option (Right to Buy)	$10.92	12/16/2017		A		600,000		⁽¹⁰⁾	12/16/2027	Common Stock	600,000	$0.00	600,000	D
Stock Option (Right to Buy)	$7.3	12/18/2017		M			226,874	⁽¹¹⁾	04/01/2025	Common Stock	226,874	$0.00	226,876	D
Stock Option (Right to Buy)	$5.94	12/18/2017		M			16,835	05/03/2017	05/03/2023	Common Stock	16,835	$0.00	0.00	D
Stock Option (Right to Buy)	$3.61	12/18/2017		M			110,800	⁽¹²⁾	04/26/2022	Common Stock	110,800	$0.00	0.00	D
Stock Option (Right to Buy)	$3.61	12/19/2017		M			133,380	⁽¹²⁾	04/26/2022	Common Stock	133,380	$0.00	755,820	D
Stock Option (Right to Buy)	$4.63	12/19/2017		M			79,688	⁽¹³⁾	04/01/2024	Common Stock	79,688	$0.00	345,312	D
Stock Option (Right to Buy)	$5.94	12/19/2017		M			333,165	⁽¹⁴⁾	05/03/2023	Common Stock	333,165	$0.00	0.00	D

Explanation of Responses:

1. Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on December 27, 2016 as a result of the vesting of one fourth of such RSUs.

2. Includes 37,812 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs.

3. Represents shares withheld to satisfy tax withholding obligations of the reporting person.

4. Includes 37,812 unvested RSUs awarded on April 1, 2015 to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock and which were reported by the reporting person on Table I on a form 4 filed upon grant of the RSUs.

5. These trades were made pursuant to a Rule 10b5-1 trading plan.

6. The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request.

7. The RSUs vested on December 16, 2017.

8. Consists of remaining unvested RSUs awarded to the reporting person for no additional cash consideration on December 16, 2016, which vest in three equal remaining installments beginning December 16, 2018, and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The grant of these RSUs were previously reported on a Table II of a form 4 filed by the reporting person.

9. Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2018.

10. The option vests in four equal annual installments beginning on December 16, 2018.

11. The option vests in four equal annual installments beginning on April 1, 2016.

12. The option vested in four equal annual installments beginning on April 26, 2013.

13. The option vests in four equal annual installments beginning on April 1, 2015.

14. The option vested in four equal annual installments beginning on May 3, 2014.

Remarks:

	Jason Haddock, attorney-in-fact for Ron Squarer	12/19/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Array Form 4ARRAY BIOPHARMA / Ron Squarer ownership change